Metabolic Dysfunction as a Rising Barrier to HBV Elimination
Journal of Gastroenterology and Hepatology · 13.11.2026
DOI: 10.1111/jgh.70879 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Gastroenterology and Hepatology, online erschienen am 13.11.2026. Verfasst von Shang-Chin Huang und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, National Taiwan University Hospital Bei-Hu Branch, Taipei, Taiwan. Die Arbeit nennt 56 Literaturangaben.
Abstract (Originalsprache)
About one‐third of patients with chronic hepatitis B (CHB) have hepatic steatosis, and cardiometabolic risk factors are increasingly prevalent. This review examines what metabolic dysfunction does to the measurements on which the elimination cascade depends, from prevention through diagnosis, treatment eligibility, on‐treatment risk control, and functional cure to postcure surveillance. Metabolic dysfunction lowers the response to adult vaccination, enters three of the four routes to treatment eligibility in the World Health Organization criteria, contributes to the hepatocellular carcinoma risk that persists during antiviral therapy, and is absent from most risk scores and surveillance rules used before and after hepatitis B surface antigen loss. Its two components diverge: hepatic steatosis and cardiometabolic burden appear to additively increase the probability of hepatitis B surface antigen loss, but act in opposite directions on cirrhosis, hepatocellular carcinoma, and mortality. Assessing and correcting metabolic dysfunction as part of CHB care, and including patients with CHB in trials of metabolic therapy, would allow success to be defined by liver outcomes rather than by the virus alone.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, National Taiwan University Hospital Bei-Hu Branch, Taipei, Taiwan.
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
- Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan.
- Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan.
ORCID-Profile: Shang-Chin Huang, Chun-Jen Liu
Zitieren
APA
Huang, S. C., & Liu, C. J. (2026). Metabolic Dysfunction as a Rising Barrier to HBV Elimination. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.70879
Vancouver
Huang SC, Liu CJ. Metabolic Dysfunction as a Rising Barrier to HBV Elimination. Journal of Gastroenterology and Hepatology. 2026. doi:10.1111/jgh.70879
BibTeX
@article{Huang2026,
author = {Huang, Shang-Chin and Liu, Chun-Jen},
title = {Metabolic Dysfunction as a Rising Barrier to HBV Elimination},
journal = {Journal of Gastroenterology and Hepatology},
year = {2026},
doi = {10.1111/jgh.70879}
}
EUVIMED